Cargando…

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

BACKGROUND: BUP-XR (SUBLOCADE(®)) is the first buprenorphine extended-release subcutaneous injection approved in the USA for monthly treatment of moderate-to-severe opioid use disorder (OUD). Among patients with OUD, those who inject or use high doses of opioids likely require higher doses of bupren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenwald, Mark K., Wiest, Katharina L., Haight, Barbara R., Laffont, Celine M., Zhao, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693082/ https://www.ncbi.nlm.nih.gov/pubmed/38042801 http://dx.doi.org/10.1186/s12954-023-00906-7

Ejemplares similares

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers
por: Duncan, Laura G., et al.
Publicado: (2015)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Does buprenorphine maintenance improve the quality of life of opioid users?
por: Dhawan, A., et al.
Publicado: (2013)

Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
por: Vierke, Christopher, et al.
Publicado: (2020)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
por: D'Agnone, Oscar
Publicado: (2019)

A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2012)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine
por: Pande, Leana J., et al.
Publicado: (2023)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
por: Heidbreder, Christian, et al.
Publicado: (2023)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Systematic Review of the Safety and Tolerability of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults With Opioid Dependence
por: Williams, Laura, et al.
Publicado: (2023)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder
por: Fox, Aaron D, et al.
Publicado: (2015)

Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study
por: Bandawar, Mrunal, et al.
Publicado: (2015)

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment
por: Lapeyre-Mestre, Maryse
Publicado: (2020)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
por: Ling, Walter, et al.
Publicado: (2019)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood
por: Leventelis, Christonikos, et al.
Publicado: (2019)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
por: Marsden, John, et al.
Publicado: (2022)

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation
por: Lowry, Natalie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7iel7ji44unomfls1enkaht0cp